Clinical Trial: Menin Inhibitors in Pediatric Relapsed or Refractory Acute Leukemia

U.S., Oct. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07898436) titled 'Menin Inhibitors in Pediatric Relapsed or Refractory Acute Leukemia' on Oct. 20.

Brief Summary: Acute leukemia is the most common childhood cancer. Despite advances in targeted therapies and immunotherapies, treatment remains challenging for children with relapsed or refractory acute leukemia, particularly those with KMT2A rearrangements, NPM1 mutations, or NUP98 rearrangements. Menin inhibitors have shown promising antileukemic activity in these molecular subgroups.

This French national, multicenter, retrospective observational study will describe the pediatric population treated with menin inhibitors for relapsed or refractory ac...